Infliximab

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Ankylosing Spondylitis

Conditions

Ankylosing Spondylitis

Trial Timeline

Oct 1, 2010 → Jun 1, 2012

NCT ID

NCT01220518

About Infliximab

Infliximab is a phase 1 stage product being developed by Celltrion for Ankylosing Spondylitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01220518. Target conditions include Ankylosing Spondylitis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04922827	Phase 2	Completed	Jun 18, 2021	Jul 1, 2023	COVID-19
NCT01571219	Phase 3	Completed	Mar 1, 2012	Jul 1, 2013	Rheumatoid Arthritis
NCT01571206	Phase 1	Completed	Mar 1, 2012	May 1, 2013	Ankylosing Spondylitis
NCT01220518	Phase 1	Completed	Oct 1, 2010	Jun 1, 2012	Ankylosing Spondylitis
NCT01217086	Phase 3	Completed	Oct 1, 2010	Jul 1, 2012	Rheumatoid Arthritis

Competing Products

20 competing products in Ankylosing Spondylitis

See all competitors

Product	Company	Stage	Hype Score
Infliximab	Celltrion	Phase 1	33
SUNPG1622 I dose + Placebo dose	Sun Pharmaceutical	Phase 2	52
adalimumab	Eisai	Phase 3	77
Ixekizumab + Placebo + Adalimumab	Eli Lilly	Phase 3	77
Tramadol /acetaminophen + Diclofenac	Johnson & Johnson	Approved	85
Golimumab + Placebo	Johnson & Johnson	Phase 3	77
Golimumab	Johnson & Johnson	Approved	85
SHR0302 + SHR0302 placebo	Jiangsu Hengrui Medicine	Phase 2/3	65
placebo for risankizumab + risankizumab	AbbVie	Phase 2	52
Adalimumab	AbbVie	Approved	85
Upadacitinib + Placebo	AbbVie	Phase 2	52
Adalimumab	AbbVie	Pre-clinical	23
infliximab + Placebo	Merck	Phase 3	77
Infliximab	Merck	Approved	85
Infliximab + Placebo + Naproxen	Merck	Phase 3	77
Infliximab	Merck	Pre-clinical	23
Golimumab	Merck	Approved	85
Remicade	Merck	Approved	85
Remicade	Merck	Approved	85
Infliximab	Merck	Approved	85

Other Products from Celltrion

Azathioprine + PlaceboApproved

Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)Approved

Infliximab + Infliximab + InfliximabApproved

Pioglitazone + Alogliptin + Alogliptin + Metformin + DapagliflozinApproved

Pioglitazone 15 MG [Actos] + Empagliflozin 10 MG [Jardiance] + Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]Approved